(NASDAQ: ASND) Ascendis Pharma A's forecast annual revenue growth rate of 69.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 88.41%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Ascendis Pharma A's revenue in 2025 is $418,978,409.On average, 6 Wall Street analysts forecast ASND's revenue for 2025 to be $50,714,927,054, with the lowest ASND revenue forecast at $47,818,460,597, and the highest ASND revenue forecast at $54,673,338,154. On average, 6 Wall Street analysts forecast ASND's revenue for 2026 to be $89,563,724,230, with the lowest ASND revenue forecast at $75,604,535,325, and the highest ASND revenue forecast at $113,024,459,220.
In 2027, ASND is forecast to generate $124,068,003,790 in revenue, with the lowest revenue forecast at $95,851,155,083 and the highest revenue forecast at $155,660,037,627.